



AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:


1. (Currently amended) ~~The compounds~~ A compound according to the general formula Ia or Ib:



wherein in each,

R1 ~~means is~~ H, C₁-C₆ alkyl, cycloalkyl, or C₁-C₄ alkylcycloalkyl, alkylcycloalkyl;

R2 ~~means~~ is C₁-C₁₄ alkyl, C₂-C₁₄ alkenyl, C₁-C₄ alkylaryl, heteroaryl, C₁-C₄ alkyl heteroaryl, cycloalkyl, C₁-C₄ alkyl-cycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, C_mH_{2m+o-p}Y_p (with ~~m = 1 to 6, for o = 1, p = 1 to 2m+o; for m = 2 to 6, o = 1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = 1 to 2m+o~~; Y ~~independently from each other selected from the group consisting of~~ halogen, OH, OR₂₁, NH₂, NHR₂₁, NR₂₁R₂₂, SH, SR₂₁), CH₂NHCOR₂₁, CH₂NHCSR₂₁, CH₂S(O)_nR₂₁, with n = 0, 1, 2, CH₂SCOR₂₁, CH₂OSO₂-R₂₁, CHO, CH=NOH, CH(OH)R₂₁, -CH=NOR₂₁, -CH=NOCOR₂₁, -CH=NOCH₂CONR₂₁R₂₂, -CH=NOCH(CH₃)CONR₂₁R₂₂, -CH=NOC(CH₃)₂CONR₂₁R₂₂, -CH=N-NHCO-R₂₃, -CH=N-NHCO-CH₂NHCOR₂₁, -CH=N-O-CH₂NHCOR₂₁, -CH=N-NHCS-R₂₃, -CH=CR₂₄R₂₅ (trans or cis), COOH, COOR₂₁,



CONR₂₁R₂₂, -CH=NR₂₁, -CH=N-NR₂₁R₂₂, , with X' =
~~NR₂₁₅, O, S, and R₂₁₁, R₂₁₂, R₂₁₃, R₂₁₄, R₂₁₅ being independently from each other H or C₁-C₆ alkyl~~, -CH=N-NHSO₂ aryl, or -CH=N-NHSO₂ heteroaryl, heteroaryl;
wherein, m is 1 to 6, o is 1, p is 1 to 2m+o;
m is 2 to 6, o is -1, p is 1 to 2m+o; or
m is 4 to 6, o is -2, p is 1 to 2m+o; and
Y independently from each other is selected from the group consisting of halogen, OH, OR₂₁, NH₂, NHR₂₁, NR₂₁R₂₂, SH and SR₂₁; and
wherein X' is NR₂₁₅, O, or S; and R₂₁₁, R₂₁₂, R₂₁₃, R₂₁₄, and R₂₁₅ are independently from each other H or C₁-C₆ alkyl;

R₂₁, R₂₂ are independently from each other C₁-C₁₄ alkyl, C₁-C₁₄ alkanoyl, C₁-C₆ alkylhydroxy, C₁-C₆ alkylamino, C₁-C₆ alkylamino-C₁-C₆ alkyl, C₁-C₆ alkylamino-di-C₁-C₆ alkyl, cycloalkyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, aryl, aryloyl, C₁-C₄ alkylaryl, heteroaryl, heteroaryloyl, C₁-C₄ alkylheteroaryl, cycloalkanoyl, C₁-C₄ alkanoylcycloalkyl, heterocycloalkanoyl, C₁-C₄ alkanoylheterocycloalkyl, C₁-C₄ alkanoylaryl, C₁-C₄ alkanoylheteroaryl, or mono- and di-sugar residues linked through a C atom which would carry an OH residue group in the sugar, wherein the sugars are independently from each other

selected from the group consisting of glucuronic acid and its stereo isomers at all optical C-atoms, aldopentoses, and aldohexoses, including their desoxy compounds (~~such as e.g. glucose, desoxyglucose, ribose, desoxyribose~~);

R23 independently of R21, ~~has the same meanings as is~~ R21, ~~or~~ CH₂-pyridinium salts, or CH₂-tri-C₁-C₆ alkylammonium salts, salts;

R24 independently of R21, ~~has the same meanings as is~~ R21, ~~or~~ H, CN, COCH₃, COOH, COOR21, CONR21R22, NH₂, ~~NHCOR21~~, or NHCOR21;

R25 independently of R21, ~~has the same meanings as is~~ R21, ~~or~~ H, CN, COCH₃, COOH, COOR21, CONR21R22, NH₂, ~~NHCOR21~~, or NHCOR21;

R24, R25 together ~~mean~~ are C₄-C₈ ~~cycloalkyl~~, cycloalkyl;

R3 ~~means is~~ H, F, Cl, Br, I, OH, OR31, NO₂, NH₂, NHR31, NR31R32, NHCHO, NHCOR31, NHCOCF₃, CH₃-_mhal_m (~~with hal = Cl, F, especially F, and m = 1, 2, 3~~), or OCOR31, wherein hal is Cl or F and m is 1, 2 or 3;

R31, 32 independently from each other ~~mean~~ are C₁-C₆ ~~alkyl~~, alkyl;

R5, R6 Independently from each other ~~mean~~ are H, C₁-C₁₄ alkyl, C₂-C₁₄ alkenyl, aryl, C₁-C₄ alkylaryl, heteroaryl, C₁-C₄ alkylheteroaryl, cycloalkyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, C_mH_{2m+o-p}Y_p (~~with m = 1 to 6, for o = 1, p = 1 to 2m+o; for m = 2 to 6, o = -1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = 1 to 2m+o; Y =~~ independently selected from the group consisting of halogen, OH, OR21, NH₂, NHR21, NR21R22, ~~SH, SR21~~), or R5 and R6, together with X₁-C-C-X₂, form a ring with 5, 6, or 7 members,
wherein, m is 1 to 6, o is 1, p is 1 to 2m+o;
m is 2 to 6, o is -1, p is 1 to 2m+o; or

m is 4 to 6, o is -2, p is 1 to 2m+o; and

Y independently from each other is selected from the group consisting of halogen, OH, OR21, NH₂, NHR21, NR21R22, SH and SR21;

R4, R7, R8 independently from each other ~~mean~~ are H, C₁-C₆ alkyl, ~~CO-R41, CO-R41;~~

R41 independently from R21 ~~has the same meanings as R21, is R21;~~

X1 ~~means is~~ is O, S, NH, N-C₁-C₈ alkyl, ~~N-cycloalkyl, or N-cycloalkyl;~~

X2 ~~means is~~ is O, S, NH, N-C₁-C₈ alkyl, ~~N-cycloalkyl, or N-cycloalkyl;~~

Y1 ~~means is~~ is O, or N-R9, wherein R9 ~~can~~, independently from R5, ~~adopt the same meanings as R5, is R5;~~



Y2 ~~means is~~ is O, or N-R10, wherein R10 ~~can~~, independently from R5, ~~adopt the same meanings as R5, is R5;~~

and, if Y1 or Y2 are N-R9 or N-R10, X2-R6 may be ~~H, H;~~

Y3 ~~means is~~ is O, S, NH, or NH;

~~as well their stereoisomers, tautomers, and their physiologically tolerable salts or inclusion compounds~~ or a stereoisomer, tautomer or physiologically tolerable salt thereof.

2. (Currently amended) The ~~compounds~~ compound according to claim 1, wherein Formula Ia or Ib adopt the stereochemistry of Formula IIa or IIb




3. (Canceled)

4. (Currently amended) The ~~compounds~~ compound according to ~~one of~~ claim 1, wherein R1 ~~means is~~ is H, C₁-C₅ alkyl, ~~cycloalkyl, especially H, or cycloalkyl;~~

R2 ~~means is~~ is C₁-C₅ alkyl, C₁-C₄ alkylaryl, C₂-C₅ alkenyl, heteroaryl, C₁-C₄ alkylheteroaryl, CHF₂, CF₃, polyol side chain, ~~particularly~~ particularly CHOH-CHOH-CHOH-CHOH-CH₃, CHOH-CHOH-CH=CH-CH₃, CH=CH-CHOH-CHOH-CH₃, CH₂Y (Y=F, Cl, Br, I), CH₂NH₂, CH₂NR₂₁R₂₂, CH₂NHCOR₂₃, CH₂NHCSR₂₃, CH₂SH, CH₂S(O)_nR₂₁, ~~with n=0, 1, 2,~~ CH₂SCOR₂₁, ~~particularly~~ particularly CH₂OH, CH₂OR₂₁, CH₂OSO₂-R₂₁, ~~particularly~~ particularly CHO, CH(OR₂₁)₂, CH(SR₂₁)₂,

CN, CH=NOH, CH=NOR21, CH=NOCOR21, CH=N-NHCO-R23, CH=CR24, R25 (trans or cis), ~~particularly COOH (particularly their physiologically tolerable salts),~~ COOR21,



CONR21R22, -CH=NR21, -CH=N-NR21R22,

(with $X' = \text{NR}_{215}, \text{O}, \text{S}$, and $\text{R}_{211}, \text{R}_{212}, \text{R}_{213}, \text{R}_{214}, \text{R}_{215}$ being independently from each other H or $\text{C}_1\text{-C}_6$ alkyl), -CH=N-NHSO₂ aryl, -CH=N-NHSO₂ heteroaryl, or CH=N-NHCO-R23, wherein Y is F, Cl, Br or I; and
wherein X' is NR₂₁₅, O, or S; and R₂₁₁, R₂₁₂, R₂₁₃, R₂₁₄, and R₂₁₅ are independently from each other H or $\text{C}_1\text{-C}_6$ alkyl;

R21, R22 independently from each other ~~mean~~ are $\text{C}_1\text{-C}_6$ alkyl, cycloalkyl, aryl, $\text{C}_1\text{-C}_4$ alkylaryl, heteroaryl, ~~$\text{C}_1\text{-C}_4$ alkylheteroaryl,~~ or $\text{C}_1\text{-C}_4$ alkylheteroaryl;

R23 independently of R21, ~~has the same meanings as is~~ is R21, ~~or a CH_2 -pyridinium salts, salt,~~
~~or a CH_2 -tri- $\text{C}_1\text{-C}_6$ alkylammonium salts, salt;~~

R24 independently of R21, ~~has the same meanings as is~~ is R21, or H, CN, COCH₃, COOH, COOR21, CONR21R22, NH₂, ~~NHCOR21,~~ or NHCOR21;

R25 independently of R21, ~~has the same meanings as is~~ is R21, or H, CN, COCH₃, COOH, COOR21, CONR21R22, NH₂, ~~NHCOR21,~~ or NHCOR21;

R24, R25 together ~~mean $\text{C}_4\text{-C}_8$ cycloalkyl,~~ are $\text{C}_4\text{-C}_8$ cycloalkyl;

R3 ~~means is~~ is F, Cl, Br, I, NO₂, NH₂, ~~NHCOR31,~~ or NHCOR31;

R31 independently from each other ~~means $\text{C}_1\text{-C}_6$ alkyl,~~ is $\text{C}_1\text{-C}_6$ alkyl;

R5, R6 independently from each other ~~mean~~ are H, C₁-C₁₄ alkyl, C₂-C₁₄ alkenyl, aryl, C₁-C₄ alkylaryl, heteroaryl, C₁-C₄ alkylheteroaryl, cycloalkyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, C_mH_{2m+o-p}Y_p (~~with m = 1 to 6, for o = 1, p = 1 to 2m+o; for m = 2 to 6, o = -1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = 1 to 2m+o; Y =~~ independently selected from the group consisting of halogen, OH, OR21, NH₂, NHR21, NR21R22, SH, SR21), or R5 and R6, together with X₁-C-C-X₂, form a ring with 5, 6, or 7 members,

wherein, m is 1 to 6, o is 1, p is 1 to 2m+o;

m is 2 to 6, o is -1, p is 1 to 2m+o; or

m is 4 to 6, o is -2, p is 1 to 2m+o; and

Y independently from each other is selected from the group consisting of halogen, OH, OR21, NH₂, NHR21, NR21R22, SH and SR21;

R4, R7, R8 independently from each other ~~mean~~ are H, C₁-C₆ alkyl, ~~CO-R41,~~ or CO-R41;

R41 independently from R21 ~~has the same meanings as R21,~~ is R21;

Y3 ~~means O, S, preferably O,~~ is O or S;

~~as well their stereoisomers, tautomers, and their physiologically tolerable salts or inclusion compounds.~~ or a stereoisomer, tautomer or physiologically tolerable salt thereof.


5. (Currently amended) The compounds according to claim 1 in the form of their inclusion compounds with cyclodextrin, ~~particularly alpha-cyclodextrin.~~

Claims 6-12. (Canceled)

13. (Currently amended) The ~~compounds~~ compound according to claim 2 wherein

R1 ~~means~~ is H, C₁-C₅ alkyl, or cycloalkyl, ~~especially H;~~

R2 means is C₁-C₅ alkyl, C₁-C₄ alkylaryl, C₂-C₅ alkenyl, heteroaryl, C₁-C₄ alkylheteroaryl, CHF₂, CF₃, polyol side chain, ~~particularly~~ CHOH-CHOH-CHOH-CHOH-CH₃, CHOH-CHOH-CH=CH-CH₃, CH=CH-CHOH-CHOH-CH₃, CH₂Y (Y = F, Cl, Br, I), CH₂NH₂, CH₂NR₂₁R₂₂, CH₂NHCOR₂₃, CH₂NHCSR₂₃, CH₂SH, CH₂S(O)_nR₂₁, ~~with n = 0, 1, 2~~, CH₂SCOR₂₁, ~~particularly~~ CH₂OH, CH₂OR₂₁, CH₂OSO₂-R₂₁, ~~particularly~~ CHO, CH(OR₂₁)₂, CH(SR₂₁)₂, CN, CH=NOH, CH=NOR₂₁, CH=NOCOR₂₁, CH=N-NHCO-R₂₃, CH=CR₂₄, R₂₅ (trans or cis), ~~particularly~~ COOH (~~particularly their physiologically tolerable salts~~), COOR₂₁,



CONR₂₁R₂₂, -CH=NR₂₁, -CH=N-NR₂₁R₂₂,
 (with X' = NR₂₁₅, O, S, and R₂₁₁, R₂₁₂, R₂₁₃, R₂₁₄, R₂₁₅ being independently from each other H or C₁-C₆ alkyl), -CH=N-NHSO₂ aryl, -CH=N-NHSO₂ heteroaryl, CH=N-NHCO-R₂₃,
wherein Y is F, Cl, Br or I;
n is 0, 1 or 2; and
wherein X' is NR₂₁₅, O, or S; and R₂₁₁, R₂₁₂, R₂₁₃, R₂₁₄, and R₂₁₅ are independently from each other H or C₁-C₆ alkyl;

R₂₁, R₂₂ independently from each other ~~mean~~ are C₁-C₆ alkyl, cycloalkyl, aryl, C₁-C₄ alkylaryl, heteroaryl, ~~C₁-C₄ alkylheteroaryl~~, or C₁-C₄alkylheteroaryl;

R₂₃ independently of R₂₁, ~~has the same meanings as is~~ is R₂₁, ~~or a CH₂-pyridinium salts, salt,~~
~~or a CH₂-tri-C₁-C₆ alkylammonium salts, salt;~~

R₂₄ independently of R₂₁, ~~has the same meanings as is~~ is R₂₁, ~~or H, CN, COCH₃, COOH,~~
~~COOR₂₁, CONR₂₁R₂₂, NH₂, NHCOR₂₁~~, or NHCOR₂₁;

R₂₅ independently of R₂₁, ~~has the same meanings as is~~ is R₂₁, ~~or H, CN, COCH₃, COOH,~~
~~COOR₂₁, CONR₂₁R₂₂, NH₂, NHCOR₂₁~~, or NHCOR₂₁;

R24, R25 together ~~mean C₄-C₈ cycloalkyl~~, are C₄-C₈ cycloalkyl;

R3 means is F, Cl, Br, I, NO₂, NH₂, NHCOR31, or NHCOR31;

R31 independently from each other ~~means C₁-C₆ alkyl~~, is C₁-C₆ alkyl;

R5, R6 independently from each other ~~mean~~ are H, C₁-C₁₄ alkyl, C₂-C₁₄ alkenyl, aryl, C₁-C₄ alkylaryl, heteroaryl, C₁-C₄ alkylheteroaryl, cycloalkyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, C_mH_{2m+o-p}Y_p (~~with m = 1 to 6, for o = 1, p = 1 to 2m+o; for m = 2 to 6, o = -1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = 1 to 2m+o; Y =~~ independently selected from the group consisting of halogen, OH, OR21, NH₂, NHR21, ~~NR21R22, SH, SR21~~), or R5 and R6, together with X₁-C-C-X₂, form a ring with 5, 6, or 7 members,

wherein, m is 1 to 6, o is 1, p is 1 to 2m+o;

m is 2 to 6, o is -1, p is 1 to 2m+o; or

m is 4 to 6, o is -2, p is 1 to 2m+o; and

Y independently from each other is selected from the group consisting of halogen, OH, OR21, NH₂, NHR21, NR21R22, SH and SR21;

R4, R7, R8 independently from each other ~~mean~~ are H, C₁-C₆ alkyl, ~~CO-R41~~, or CO-R41;

R41 independently from R21 ~~has the same meanings as R21~~, is R21;

Y3 ~~means O, S, preferably O~~, is O or S;

~~as well their stereoisomers, tautomers, and their physiologically tolerable salts or inclusion compounds~~ a stereoisomer, tautomer or physiologically tolerable salt thereof.

Claims 14 – 15 (Canceled)

16. (New) A method of treating a tumor comprising the step of administering to a patient having a tumor selected from the group consisting of lung, renal, prostate, uterine, melanoma and breast tumors an amount of a compound of claim 1 effective to treat said tumor.

17. (New) The method of claim 16 wherein said tumor is a lung tumor.

18. (New) The method of claim 16 wherein said tumor is a renal tumor.

19. (New) The method of claim 16 wherein said tumor is a prostate tumor.

20. (New) The method of claim 16 wherein said tumor is a uterine tumor.

21. (New) The method of claim 16 wherein said tumor is a melanoma.

22. (New) The method of claim 16 wherein said tumor is a breast tumor.

23. (New) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or adjuvant.

24. (New) A method of treating a tumor comprising the step of administering to a patient having a tumor selected from the group consisting of lung, renal, prostate, uterine, melanoma and breast tumors an amount of a compound of claim 2 effective to treat said tumor.

25. (New) The method of claim 24 wherein said tumor is a lung tumor.

26. (New) The method of claim 24 wherein said tumor is a renal tumor.

27. (New) The method of claim 24 wherein said tumor is a prostate tumor.

28. (New) The method of claim 24 wherein said tumor is a uterine tumor.

29. (New) The method of claim 24 wherein said tumor is a melanoma.

30. (New) The method of claim 24 wherein said tumor is a breast tumor.

31. (New) A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier or adjuvant.